A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Funding: this study was funded by Sanofi. Acknowledgments: the authors thank the participating patients and their caregivers, the study centers, and the study investigators for their contributions to the study. The authors also thank Honghong Dong, MS, of Sanofi Research & Development, Bridgewat...

Descripción completa

Detalles Bibliográficos
Autores: Quach, Hang, Parmar, Gurdeep, Ocio San Miguel, Enrique María|||0000-0002-5765-0085, Prince, H. Miles, Oriol, Albert, Crowther, Helen, Tsukada, Nobuhiro, Bories, Pierre, Madan, Sumit, Nathwani, Nitya, Sunami, Kazutaka, Semiond, Dorothee, Yu, Disa, Cordero, Paul, Macé, Sandrine, Suzan, Florence, Moreau, Philippe
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/34533
Acceso en línea:https://hdl.handle.net/10902/34533
Access Level:acceso abierto
id ES_d66af65c8a6b6da07fa4fae8ffe58f66
oai_identifier_str oai:repositorio.unican.es:10902/34533
network_acronym_str ES
network_name_str España
repository_id_str
spelling A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myelomaQuach, HangParmar, GurdeepOcio San Miguel, Enrique María|||0000-0002-5765-0085Prince, H. MilesOriol, AlbertCrowther, HelenTsukada, NobuhiroBories, PierreMadan, SumitNathwani, NityaSunami, KazutakaSemiond, DorotheeYu, DisaCordero, PaulMacé, SandrineSuzan, FlorenceMoreau, PhilippeFunding: this study was funded by Sanofi. Acknowledgments: the authors thank the participating patients and their caregivers, the study centers, and the study investigators for their contributions to the study. The authors also thank Honghong Dong, MS, of Sanofi Research & Development, Bridgewater NJ, USA, for her contribution to the statistical analyses for this study, and BioCytex (a Stago Group company) for their contribution to the immunophenotyping analyses. The on-body delivery system was manufactured by Enable Injections, Inc. Medical writing support was provided by S. Mariani, MD, PhD of Envision Pharma Group, funded by Sanofi.Ferrata Storti FoundationUniversidad de Cantabria20242024-01-01journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articlehttps://hdl.handle.net/10902/34533Haematologica, 2024reponame:UCrea Repositorio Abierto de la Universidad de Cantabriainstname:Universidad de Cantabria (UC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:repositorio.unican.es:10902/345332026-06-02T12:39:31Z
dc.title.none.fl_str_mv A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
title A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
spellingShingle A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
Quach, Hang
title_short A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
title_full A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
title_fullStr A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
title_full_unstemmed A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
title_sort A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
dc.creator.none.fl_str_mv Quach, Hang
Parmar, Gurdeep
Ocio San Miguel, Enrique María|||0000-0002-5765-0085
Prince, H. Miles
Oriol, Albert
Crowther, Helen
Tsukada, Nobuhiro
Bories, Pierre
Madan, Sumit
Nathwani, Nitya
Sunami, Kazutaka
Semiond, Dorothee
Yu, Disa
Cordero, Paul
Macé, Sandrine
Suzan, Florence
Moreau, Philippe
author Quach, Hang
author_facet Quach, Hang
Parmar, Gurdeep
Ocio San Miguel, Enrique María|||0000-0002-5765-0085
Prince, H. Miles
Oriol, Albert
Crowther, Helen
Tsukada, Nobuhiro
Bories, Pierre
Madan, Sumit
Nathwani, Nitya
Sunami, Kazutaka
Semiond, Dorothee
Yu, Disa
Cordero, Paul
Macé, Sandrine
Suzan, Florence
Moreau, Philippe
author_role author
author2 Parmar, Gurdeep
Ocio San Miguel, Enrique María|||0000-0002-5765-0085
Prince, H. Miles
Oriol, Albert
Crowther, Helen
Tsukada, Nobuhiro
Bories, Pierre
Madan, Sumit
Nathwani, Nitya
Sunami, Kazutaka
Semiond, Dorothee
Yu, Disa
Cordero, Paul
Macé, Sandrine
Suzan, Florence
Moreau, Philippe
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad de Cantabria
description Funding: this study was funded by Sanofi. Acknowledgments: the authors thank the participating patients and their caregivers, the study centers, and the study investigators for their contributions to the study. The authors also thank Honghong Dong, MS, of Sanofi Research & Development, Bridgewater NJ, USA, for her contribution to the statistical analyses for this study, and BioCytex (a Stago Group company) for their contribution to the immunophenotyping analyses. The on-body delivery system was manufactured by Enable Injections, Inc. Medical writing support was provided by S. Mariani, MD, PhD of Envision Pharma Group, funded by Sanofi.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
NA
http://purl.org/coar/version/c_be7fb7dd8ff6fe43
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10902/34533
url https://hdl.handle.net/10902/34533
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Ferrata Storti Foundation
publisher.none.fl_str_mv Ferrata Storti Foundation
dc.source.none.fl_str_mv Haematologica, 2024
reponame:UCrea Repositorio Abierto de la Universidad de Cantabria
instname:Universidad de Cantabria (UC)
instname_str Universidad de Cantabria (UC)
reponame_str UCrea Repositorio Abierto de la Universidad de Cantabria
collection UCrea Repositorio Abierto de la Universidad de Cantabria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420858466893824
score 15,812429

Similares en LA Referencia